800-799-2234
Office Locations
Mon - Fri 09:00 am - 05:00 pm
Michigan's #1
Mesothelioma Law Firm
We Have Won
Thousands of Cases
Trusted By
10,000+ Clients
Immediate Assistance 24/7

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

You are here:
Estimated reading time: < 1 min

Condition: Pleural Mesothelioma|Peritoneal Mesothelioma

NCT Number: NCT01160458
Estimated Enrollment: 20
Phases: Phase 2
Age Group: 18 Years and older   (Adult, Older Adult)
Gender: All
Study Type: Interventional
Study Results: Has Results

Study Design Allocation: Allocation: Has Results

Study ID Numbers: 100146|10-C-0146
Study First Received: July 12, 2010
Last Updated: April 10, 2018
Estimated Primary Completion Date: August 13, 2016
Completion Date: February 24, 2017

Primary Outcome Measures: Clinical Response Rate (PR+CR)|Safety of IMC-A12 in Patients With Mesothelioma|Duration of Overall Response|Progression Free Survival (PFS)|Overall Survival (OS)

Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Funded By: NIH
Interventions: Drug: Drug: IMC-A12

Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT01160458

Was this article helpful?
Dislike 0
Call Now ButtonCALL NOW